Jacob A. Frenkel - 06 Apr 2022 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role: Director
Signature: /s/ Jacob A. Frenkel
Issuer symbol: BCLI
Transactions as of: 06 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 08 Apr 2022, 16:30:46 UTC
Previous filing: 10 Dec 2021
Next filing: 03 Jan 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCLI	Stock Option (right to buy)	Award	$0	+50,000		$0.000000	50,000	06 Apr 2022	Common Stock	50,000	$0.7500	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, this option shall vest and become exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2022 until fully vested and exercisable on the 12 month anniversary of April 6, 2022, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date.

Content

Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, this option shall vest and become exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2022 until fully vested and exercisable on the 12 month anniversary of April 6, 2022, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date.